Biological
ADVM-022
ADVM-022 is a biological therapy with 4 clinical trials. Currently 3 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
3(75%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
1
25%
Ph phase_1
1
25%
Phase Distribution
1
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 2Efficacy & side effects
1(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
3
trials recruiting
Total Trials
4
all time
Status Distribution
Active(3)
Completed(1)
Detailed Status
Active, not recruiting3
Completed1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
3
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (50.0%)
Phase 21 (50.0%)
Trials by Status
active_not_recruiting375%
completed125%
Recent Activity
3 active trials
Showing 4 of 4
active_not_recruiting
Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]
NCT04645212
active_not_recruitingphase_2
Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]
NCT05536973
active_not_recruiting
Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)
NCT05607810
completedphase_1
ADVM-022 Intravitreal Gene Therapy for Wet AMD
NCT03748784
Clinical Trials (4)
Showing 4 of 4 trials
NCT04645212
Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]
NCT05536973Phase 2
Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]
NCT05607810
Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)
NCT03748784Phase 1
ADVM-022 Intravitreal Gene Therapy for Wet AMD
All 4 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 4